Slate Medicines

Based in the US, Slate Medicines is a biotechnology company focused on developing novel therapeutics aimed at targeting PACAP (Pituitary adenylate cyclase-activating polypeptide) for migraine and headache disorders. Slate Medicines, founded in 2026, is headquartered in Raleigh, US, specializing in the development of therapeutics for managing migraine and headache disorders. The company recently raised USD 130. 00 mn in Series A funding on February 24, 2026, co-led by RA Capital Management, Forbion, and Foresite Capital.

The firm has conducted one deal to date and aims to use the funding to advance its lead program, SLTE-1009, into Phase 1 clinical trials. Slate Medicines is a biotechnology firm specializing in the development of innovative therapeutics aimed at targeting PACAP (Pituitary adenylate cyclase-activating polypeptide) for the management of migraine and other headache disorders. The company’s primary focus is to create next-generation therapeutics that address the underlying mechanisms of these conditions, ultimately improving patient outcomes and quality of life. Slate Medicines is engaged in advancing its pipeline of products that are designed to mitigate the frequency and severity of migraine attacks, providing relief to individuals who suffer from chronic headache disorders.

The customer base includes healthcare providers, specialists in neurology, and patients across various geographical markets, with a particular concentration in North America and Europe, where there is a significant demand for effective migraine treatments. The revenue structure of Slate Medicines is centered on business-to-business (B2B) transactions, primarily involving partnerships with healthcare institutions and pharmaceutical distributors. The company’s revenue is generated through the commercialization of its PACAP-targeting therapeutics, which may involve licensing agreements and collaborations with larger pharmaceutical entities for distribution and marketing. Potential transactions could include direct sales to hospitals and clinics, as well as partnerships with wholesalers for broader market reach.

Specific pricing plans for these therapeutics have not been disclosed, but the focus remains on establishing a sustainable revenue model through these strategic partnerships and targeted sales channels. The flagship products developed by Slate Medicines are expected to play a crucial role in their revenue generation strategy, aligning with the growing need for effective migraine treatments in the healthcare market. Slate Medicines plans to leverage the recent USD 130. 00 mn funding to advance its lead anti-PACAP monoclonal antibody program, SLTE-1009, into Phase 1 clinical trials and to progress additional therapies for migraine and other headache disorders.

The company seeks to expand its market presence, targeting specifically North America and Europe for broader distribution of its products. The funding will support these growth initiatives, enhancing their capacity to bring innovative solutions to those suffering from chronic headache disorders.